MAPK14 and atherosclerosis: In a previous study, network pharmacology was utilized to examine the therapeutic roles of canagliflozin and dapagliflozin in atherosclerosis, revealing that these drugs act by targeting key molecules such as Akt1, MAPK1, MAPK14, SRC, and EGFR [43].